0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-34L16729
Home | Market Reports | People & Society
Global Age Related Macular Degeneration AMD Treatment Drugs Market Research Report 2024
BUY CHAPTERS

Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-34L16729
Report
November 2025
Pages:153
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size

The global Age-Related Macular Degeneration (AMD) Treatment Drugs market is projected to grow from US$ 10720 million in 2024 to US$ 15710 million by 2031, at a CAGR of 5.7% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Age-Related Macular Degeneration (AMD) Treatment Drugs Market

Age-Related Macular Degeneration (AMD) Treatment Drugs Market

Age-related macular degeneration (AMD) is a progressive eye disease that affects the macula, a part of the retina responsible for central vision. The cells in the macula become damaged and begin to die, causing vision loss as a person ages. The disease is typically categorized into two types: dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). Dry AMD is more common and involves the formation of small, yellow deposits in the macula, while wet AMD is less common and involves the growth of abnormal blood vessels beneath the macula. In dry AMD, treatment options include vitamin supplements and lifestyle changes to reduce risk factors. In wet AMD, treatment involves medications that are injected into the eye to stop the growth of abnormal blood vessels. This treatment is called abnormal endothelial growth factor (anti-VEGF) therapy, and it works by blocking the protein that stimulates the growth of abnormal blood vessels.
The age-related macular degeneration (AMD) market trends are shaping the growth of the market. For instance rise in the adoption of age-related macular degeneration drugs (AMD) among the geriatric population suffering from age-related macular degeneration (AMD) drives the growth of the age-related macular degeneration (AMD) market size. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over, indicating a potential increase in the age-related macular degeneration (AMD) market size.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Age-Related Macular Degeneration (AMD) Treatment Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Age-Related Macular Degeneration (AMD) Treatment Drugs Market Report

Report Metric Details
Report Name Age-Related Macular Degeneration (AMD) Treatment Drugs Market
Accounted market size in 2024 US$ 10720 million
Forecasted market size in 2031 US$ 15710 million
CAGR 5.7%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • Aflibercept
  • Ranibizumab
  • Others
Segment by Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, AbbVie, Pfizer Inc., Amgen Inc., Samsung Bioepis
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Age-Related Macular Degeneration (AMD) Treatment Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Age-Related Macular Degeneration (AMD) Treatment Drugs Market growing?

Ans: The Age-Related Macular Degeneration (AMD) Treatment Drugs Market witnessing a CAGR of 5.7% during the forecast period 2025-2031.

What is the Age-Related Macular Degeneration (AMD) Treatment Drugs Market size in 2031?

Ans: The Age-Related Macular Degeneration (AMD) Treatment Drugs Market size in 2031 will be US$ 15710 million.

Who are the main players in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market report?

Ans: The main players in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market are Ionis Pharmaceuticals, Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Biogen, Novartis AG, Sanofi S.A., Bayer AG, Coherus Biosciences Inc, F. Hoffmann-La Roche Ltd, Apellis Pharmaceuticals Inc, AbbVie, Pfizer Inc., Amgen Inc., Samsung Bioepis

What are the Application segmentation covered in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market report?

Ans: The Applications covered in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market report?

Ans: The Types covered in the Age-Related Macular Degeneration (AMD) Treatment Drugs Market report are Aflibercept, Ranibizumab, Others

1 Study Coverage
1.1 Introduction to Age-Related Macular Degeneration (AMD) Treatment Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Aflibercept
1.2.3 Ranibizumab
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Aflibercept Market Size by Manufacturers
3.5.2 Ranibizumab Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Ionis Pharmaceuticals, Inc
11.1.1 Ionis Pharmaceuticals, Inc Corporation Information
11.1.2 Ionis Pharmaceuticals, Inc Business Overview
11.1.3 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.1.4 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Product in 2024
11.1.6 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application in 2024
11.1.7 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Area in 2024
11.1.8 Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
11.1.9 Ionis Pharmaceuticals, Inc Recent Developments
11.2 Bausch Health Companies Inc
11.2.1 Bausch Health Companies Inc Corporation Information
11.2.2 Bausch Health Companies Inc Business Overview
11.2.3 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.2.4 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Product in 2024
11.2.6 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application in 2024
11.2.7 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Area in 2024
11.2.8 Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
11.2.9 Bausch Health Companies Inc Recent Developments
11.3 Regeneron Pharmaceuticals Inc
11.3.1 Regeneron Pharmaceuticals Inc Corporation Information
11.3.2 Regeneron Pharmaceuticals Inc Business Overview
11.3.3 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.3.4 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Product in 2024
11.3.6 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application in 2024
11.3.7 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Area in 2024
11.3.8 Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
11.3.9 Regeneron Pharmaceuticals Inc Recent Developments
11.4 Biogen
11.4.1 Biogen Corporation Information
11.4.2 Biogen Business Overview
11.4.3 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.4.4 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Product in 2024
11.4.6 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application in 2024
11.4.7 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Area in 2024
11.4.8 Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
11.4.9 Biogen Recent Developments
11.5 Novartis AG
11.5.1 Novartis AG Corporation Information
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.5.4 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Product in 2024
11.5.6 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application in 2024
11.5.7 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Geographic Area in 2024
11.5.8 Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
11.5.9 Novartis AG Recent Developments
11.6 Sanofi S.A.
11.6.1 Sanofi S.A. Corporation Information
11.6.2 Sanofi S.A. Business Overview
11.6.3 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.6.4 Sanofi S.A. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Sanofi S.A. Recent Developments
11.7 Bayer AG
11.7.1 Bayer AG Corporation Information
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.7.4 Bayer AG Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Bayer AG Recent Developments
11.8 Coherus Biosciences Inc
11.8.1 Coherus Biosciences Inc Corporation Information
11.8.2 Coherus Biosciences Inc Business Overview
11.8.3 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.8.4 Coherus Biosciences Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Coherus Biosciences Inc Recent Developments
11.9 F. Hoffmann-La Roche Ltd
11.9.1 F. Hoffmann-La Roche Ltd Corporation Information
11.9.2 F. Hoffmann-La Roche Ltd Business Overview
11.9.3 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.9.4 F. Hoffmann-La Roche Ltd Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 F. Hoffmann-La Roche Ltd Recent Developments
11.10 Apellis Pharmaceuticals Inc
11.10.1 Apellis Pharmaceuticals Inc Corporation Information
11.10.2 Apellis Pharmaceuticals Inc Business Overview
11.10.3 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.10.4 Apellis Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Apellis Pharmaceuticals Inc Recent Developments
11.11 AbbVie
11.11.1 AbbVie Corporation Information
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.11.4 AbbVie Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 AbbVie Recent Developments
11.12 Pfizer Inc.
11.12.1 Pfizer Inc. Corporation Information
11.12.2 Pfizer Inc. Business Overview
11.12.3 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.12.4 Pfizer Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Pfizer Inc. Recent Developments
11.13 Amgen Inc.
11.13.1 Amgen Inc. Corporation Information
11.13.2 Amgen Inc. Business Overview
11.13.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.13.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Amgen Inc. Recent Developments
11.14 Samsung Bioepis
11.14.1 Samsung Bioepis Corporation Information
11.14.2 Samsung Bioepis Business Overview
11.14.3 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Product Models, Descriptions and Specifications
11.14.4 Samsung Bioepis Age-Related Macular Degeneration (AMD) Treatment Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Samsung Bioepis Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain
12.2 Age-Related Macular Degeneration (AMD) Treatment Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Age-Related Macular Degeneration (AMD) Treatment Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Age-Related Macular Degeneration (AMD) Treatment Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Age-Related Macular Degeneration (AMD) Treatment Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Manufacturers (2020-2025)
 Table 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs as of 2024)
 Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base and Headquarters
 Table 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2026-2031) & (K Dose)
 Table 30. Age-Related Macular Degeneration (AMD) Treatment Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
 Table 37. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
 Table 40. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Investment Opportunities and Key Challenges
 Table 47. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Ionis Pharmaceuticals, Inc Corporation Information
 Table 51. Ionis Pharmaceuticals, Inc Description and Major Businesses
 Table 52. Ionis Pharmaceuticals, Inc Product Models, Descriptions and Specifications
 Table 53. Ionis Pharmaceuticals, Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. Ionis Pharmaceuticals, Inc Sales Value Proportion by Product in 2024
 Table 55. Ionis Pharmaceuticals, Inc Sales Value Proportion by Application in 2024
 Table 56. Ionis Pharmaceuticals, Inc Sales Value Proportion by Geographic Area in 2024
 Table 57. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
 Table 58. Ionis Pharmaceuticals, Inc Recent Developments
 Table 59. Bausch Health Companies Inc Corporation Information
 Table 60. Bausch Health Companies Inc Description and Major Businesses
 Table 61. Bausch Health Companies Inc Product Models, Descriptions and Specifications
 Table 62. Bausch Health Companies Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Bausch Health Companies Inc Sales Value Proportion by Product in 2024
 Table 64. Bausch Health Companies Inc Sales Value Proportion by Application in 2024
 Table 65. Bausch Health Companies Inc Sales Value Proportion by Geographic Area in 2024
 Table 66. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
 Table 67. Bausch Health Companies Inc Recent Developments
 Table 68. Regeneron Pharmaceuticals Inc Corporation Information
 Table 69. Regeneron Pharmaceuticals Inc Description and Major Businesses
 Table 70. Regeneron Pharmaceuticals Inc Product Models, Descriptions and Specifications
 Table 71. Regeneron Pharmaceuticals Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. Regeneron Pharmaceuticals Inc Sales Value Proportion by Product in 2024
 Table 73. Regeneron Pharmaceuticals Inc Sales Value Proportion by Application in 2024
 Table 74. Regeneron Pharmaceuticals Inc Sales Value Proportion by Geographic Area in 2024
 Table 75. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
 Table 76. Regeneron Pharmaceuticals Inc Recent Developments
 Table 77. Biogen Corporation Information
 Table 78. Biogen Description and Major Businesses
 Table 79. Biogen Product Models, Descriptions and Specifications
 Table 80. Biogen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. Biogen Sales Value Proportion by Product in 2024
 Table 82. Biogen Sales Value Proportion by Application in 2024
 Table 83. Biogen Sales Value Proportion by Geographic Area in 2024
 Table 84. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
 Table 85. Biogen Recent Developments
 Table 86. Novartis AG Corporation Information
 Table 87. Novartis AG Description and Major Businesses
 Table 88. Novartis AG Product Models, Descriptions and Specifications
 Table 89. Novartis AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. Novartis AG Sales Value Proportion by Product in 2024
 Table 91. Novartis AG Sales Value Proportion by Application in 2024
 Table 92. Novartis AG Sales Value Proportion by Geographic Area in 2024
 Table 93. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
 Table 94. Novartis AG Recent Developments
 Table 95. Sanofi S.A. Corporation Information
 Table 96. Sanofi S.A. Description and Major Businesses
 Table 97. Sanofi S.A. Product Models, Descriptions and Specifications
 Table 98. Sanofi S.A. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 99. Sanofi S.A. Recent Developments
 Table 100. Bayer AG Corporation Information
 Table 101. Bayer AG Description and Major Businesses
 Table 102. Bayer AG Product Models, Descriptions and Specifications
 Table 103. Bayer AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 104. Bayer AG Recent Developments
 Table 105. Coherus Biosciences Inc Corporation Information
 Table 106. Coherus Biosciences Inc Description and Major Businesses
 Table 107. Coherus Biosciences Inc Product Models, Descriptions and Specifications
 Table 108. Coherus Biosciences Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 109. Coherus Biosciences Inc Recent Developments
 Table 110. F. Hoffmann-La Roche Ltd Corporation Information
 Table 111. F. Hoffmann-La Roche Ltd Description and Major Businesses
 Table 112. F. Hoffmann-La Roche Ltd Product Models, Descriptions and Specifications
 Table 113. F. Hoffmann-La Roche Ltd Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 114. F. Hoffmann-La Roche Ltd Recent Developments
 Table 115. Apellis Pharmaceuticals Inc Corporation Information
 Table 116. Apellis Pharmaceuticals Inc Description and Major Businesses
 Table 117. Apellis Pharmaceuticals Inc Product Models, Descriptions and Specifications
 Table 118. Apellis Pharmaceuticals Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 119. Apellis Pharmaceuticals Inc Recent Developments
 Table 120. AbbVie Corporation Information
 Table 121. AbbVie Description and Major Businesses
 Table 122. AbbVie Product Models, Descriptions and Specifications
 Table 123. AbbVie Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 124. AbbVie Recent Developments
 Table 125. Pfizer Inc. Corporation Information
 Table 126. Pfizer Inc. Description and Major Businesses
 Table 127. Pfizer Inc. Product Models, Descriptions and Specifications
 Table 128. Pfizer Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 129. Pfizer Inc. Recent Developments
 Table 130. Amgen Inc. Corporation Information
 Table 131. Amgen Inc. Description and Major Businesses
 Table 132. Amgen Inc. Product Models, Descriptions and Specifications
 Table 133. Amgen Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 134. Amgen Inc. Recent Developments
 Table 135. Samsung Bioepis Corporation Information
 Table 136. Samsung Bioepis Description and Major Businesses
 Table 137. Samsung Bioepis Product Models, Descriptions and Specifications
 Table 138. Samsung Bioepis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 139. Samsung Bioepis Recent Developments
 Table 140. Key Raw Materials Distribution
 Table 141. Raw Materials Key Suppliers
 Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 143. Milestones in Production Technology Evolution
 Table 144. Distributors List
 Table 145. Market Trends and Market Evolution
 Table 146. Market Drivers and Opportunities
 Table 147. Market Challenges, Risks, and Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources


List of Figures
 Figure 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Picture
 Figure 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Aflibercept Product Picture
 Figure 4. Ranibizumab Product Picture
 Figure 5. Others Product Picture
 Figure 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospital Pharmacy
 Figure 8. Retail Pharmacy
 Figure 9. Online Pharmacy
 Figure 10. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
 Figure 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2020-2031)
 Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (2020-2031) & (K Dose)
 Figure 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume Market Share in 2024
 Figure 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Aflibercept Revenue Market Share by Manufacturer in 2024
 Figure 22. Ranibizumab Revenue Market Share by Manufacturer in 2024
 Figure 23. Others Revenue Market Share by Manufacturer in 2024
 Figure 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2020-2031)
 Figure 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2020-2031)
 Figure 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2020-2031)
 Figure 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2020-2031)
 Figure 28. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
 Figure 29. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. North America Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
 Figure 31. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020- 2031)
 Figure 32. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 33. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
 Figure 34. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 35. US Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 36. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 37. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 38. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
 Figure 39. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Europe Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
 Figure 41. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020-2031)
 Figure 42. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
 Figure 44. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 45. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. France Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. U.K. Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
 Figure 51. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Top 8 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
 Figure 53. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020- 2031)
 Figure 54. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 55. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
 Figure 56. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Indonesia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 58. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 59. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 60. China Taiwan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 61. India Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
 Figure 62. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
 Figure 63. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Central and South America Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
 Figure 65. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2021-2031)
 Figure 66. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 67. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
 Figure 68. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 69. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 70. Argentina Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 71. Middle East, and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
 Figure 72. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 73. Middle East and Africa Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
 Figure 74. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2021-2031)
 Figure 75. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 76. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
 Figure 77. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 78. GCC Countries Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 79. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 80. Egypt Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 81. South Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
 Figure 82. Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain Mapping
 Figure 83. Regional Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base Distribution (%)
 Figure 84. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Region (2020-2031)
 Figure 85. Age-Related Macular Degeneration (AMD) Treatment Drugs Production Process
 Figure 86. Regional Age-Related Macular Degeneration (AMD) Treatment Drugs Production Cost Structure
 Figure 87. Channels of Distribution (Direct Vs Distribution)
 Figure 88. Bottom-up and Top-down Approaches for This Report
 Figure 89. Data Triangulation
 Figure 90. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS